Insights - Orexigen Therapeutics (OREX) surged early this week with the release of positive interim study results for Contrave, the company’s approved weight loss drug. Public comments from an FDA official on Thursday evening, however, put a damper on the celebration.
Read nowInsights - Orexigen Therapeutics (OREX) ripped higher on Tuesday with news that a new – and profoundly important – patent has been issued for Contrave, Orexigen’s approved weight … Continue Reading
Read nowResearch - Orexigen Therapeutics (OREX) is trading at $6.00 this afternoon, one week ahead of the September 11 FDA approval decision for Contrave (NB32). We suggested buying OREX in late July at $5.20 as … Continue Reading
PremiumResearch - Orexigen Therapeutics (OREX) on Thursday reported second quarter results. We’re bullish on OREX in the near-term, but some revelations on the company’s conference call work against the … Continue Reading
Read nowResearch - Orexigen Therapeutics (OREX) has again dipped below $5.50, which we find attractive 6 weeks ahead of the September 11 PDUFA decision for NB32 (Contrave, naltrexone/bupropion), … Continue Reading
Read nowResearch - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
PremiumResearch - Orexigen's (OREX) PDUFA data is next month for NB32. The stock is off 30% from its highs, and given a high chance of an approval, the long trade is attractive.
Read now
